Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics reported second-quarter 2026 results highlighted by its first commercial revenue and a significantly strengthened cash position. Net product revenue was $3.6 million from the U.S. launch of AVLAYAH for Hunter syndrome, with cost of goods sold of $0.1 million and a net loss of $127.6 million. Research and development expenses were $97.0 million, down from $102.7 million a year earlier, while selling, general and administrative expenses rose to $36.3 million, reflecting commercial launch investments. Intangible asset amortization reached $0.7 million following AVLAYAH’s FDA approval.
Cash, cash equivalents and marketable securities were approximately $940.0 million as of June 30, 2026; after receiving $195.0 million in gross proceeds from the sale of a Priority Review Voucher in July, pro forma balances exceeded $1.1 billion. AVLAYAH’s U.S. launch generated strong initial uptake, with projected third-quarter 2026 AVLAYAH net product revenue of $10.0 million to $12.0 million and broadening payer coverage. The pipeline advanced with Phase 3 start-up for zafinofusp alfa in Sanfilippo syndrome type A, completion of enrollment in the Phase 1/2 DNL593 FTD-GRN study, and multiple Alzheimer’s, lysosomal storage disease and Pompe programs progressing, while the DNL151 LUMA study in early-stage Parkinson’s disease did not meet endpoints and development in idiopathic disease was discontinued.
Denali Therapeutics Inc. is reported to have significant ownership by investment adviser Baillie Gifford & Co, according to this amended Schedule 13G filing. Baillie Gifford & Co beneficially owns 11,960,230 shares of Denali Therapeutics common stock, representing 7.54% of the class as of June 30, 2026. The firm has sole voting power over 11,915,890 shares and sole dispositive power over 11,960,230 shares, with no shared voting or dispositive power reported. These securities are held by Baillie Gifford & Co and/or its investment adviser subsidiaries on behalf of various investment advisory clients, including institutional accounts.
Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company on July 27, 2026. The transaction was carried out under an asset purchase agreement dated June 12, 2026.
Denali received gross proceeds of $195.0 million from the buyer upon closing of the sale. The voucher had been obtained when tividenofusp alfa was approved by the U.S. Food and Drug Administration for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. Denali plans to file the full PRV Transfer Agreement as an exhibit in a subsequent Securities and Exchange Commission filing.
Denali Therapeutics Inc Schedule 13G/A reports that T. Rowe Price Investment Management, Inc. beneficially owns 16,178,963 shares of common stock, representing 10.2% of the class as stated in the filing. The filing lists CUSIP 24823R105 and identifies the reporting person as a Maryland entity. The report shows 15,639,355 shares for which the filer has sole voting power and 16,178,963 shares for which it has sole dispositive power. The filing is signed by Ellen York, Vice President, dated 07/08/2026.
Denali Therapeutics Inc. entered a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash, with closing subject to customary conditions including expiration of the Hart-Scott-Rodino waiting period. The voucher was awarded after the FDA’s accelerated approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome, in March 2026. Denali states that proceeds are intended to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases, building on its blood-brain barrier-crossing platform and expanding programs across multiple central nervous system indications.
Denali Therapeutics Inc. director Jay T. Flatley reported new equity awards in the form of common stock and stock options. He received 6,408 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock, with 100% of the RSUs vesting on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting.
Flatley was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring on June 3, 2036. Following these grants, he holds 22,628 shares directly, including 6,408 unvested RSUs, and 336,313 shares indirectly through The Flatley Family Trust, for which he serves as trustee. The filing does not show any open-market purchases or sales.
Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options. He received 6,408 shares of Common Stock in the form of RSUs, with all RSUs scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the day before the company’s next annual stockholder meeting after the grant date.
He was also granted a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, with the option vesting on the same schedule as the RSUs. Following these awards, Klein directly owns 33,941 shares of Common Stock and holds the newly granted option for 19,226 underlying shares.
Denali Therapeutics director Steve E. Krognes reported equity awards and updated holdings. He received 6,408 shares of common stock in the form of Restricted Stock Units, which will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual stockholder meeting. He was also granted stock options for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule and an expiration date in 2036. Following these grants, he holds 38,202 shares directly and 781,797 shares indirectly through The Steve Edward Krognes Revocable Trust, where he serves as trustee.
Denali Therapeutics director David P. Schenkein reported new equity awards. He received 6,408 Restricted Stock Units, each representing a contingent right to one share of common stock. These RSUs vest in full on the earlier of one year from grant or the day before the next annual stockholder meeting.
He also received a stock option for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule. After these grants, he directly holds 21,665 common shares, and additional common shares are held indirectly through the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust.
Denali Therapeutics Inc. director Nancy Thornberry reported routine equity compensation awards. She received 6,408 Restricted Stock Units, each tied to one share of common stock, which will fully vest on the earlier of one year from grant or the day before the next annual stockholder meeting.
She was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, with the same vesting schedule and expiration in 2036. Following these awards, she directly holds 31,125 shares of common stock, including the unvested RSUs.